Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-dependent L-type calcium channel subunit beta-1 (CACNB1) is a critical regulatory component of the high-voltage-activated calcium channel complex, primarily expressed in skeletal muscle and the central nervous system (UniProt, 2024; Wikipedia, 2024). As an intracellular auxiliary subunit, it belongs to the membrane-associated guanylate kinase (MAGUK) family and consists of conserved SH3 and guanylate kinase (GK) domains (HUGO Gene Nomenclature Committee, 2024). CACNB1 is essential for the functional expression of calcium channels, as it facilitates the trafficking of the pore-forming alpha-1 subunit to the plasma membrane and modulates its biophysical properties, such as increasing peak current and shifting voltage-dependent activation (NCBI Gene, 2024). In skeletal muscle, the beta-1a isoform is a key player in excitation-contraction coupling, physically linking the dihydropyridine receptor (DHPR) to the ryanodine receptor (RyR1) to trigger calcium release from the sarcoplasmic reticulum (PubMed, 1996). Pathogenic variants in the CACNB1 gene have been recently identified as the cause of a novel congenital myopathy characterized by early-onset muscle weakness, ptosis, and elevated creatine kinase levels (PubMed, 2023; PMC, 2024). While traditional calcium channel blockers like dihydropyridines primarily bind the alpha-1 subunit, the beta-1 subunit is an emerging target for therapeutic strategies aimed at modulating channel assembly and trafficking in neuromuscular and neurodegenerative diseases (PubMed, 2012; MDPI, 2024).
Modulates the pore-forming alpha-1 subunit by increasing peak calcium current, shifting the voltage-dependence of activation and inactivation, and facilitating membrane trafficking of the channel complex (UniProt, 2024; NCBI Gene, 2024).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-dependent L-type calcium channel subunit beta-1 (CACNB1) (CACNB1).